Cellectar Biosciences, Inc. (NASDAQ:CLRB) has a beta value of 1.59 and has seen 1,812,773 shares traded in the last trading session. The company, currently valued at $91.73 Million, closed the last trade at $2.02 per share which meant it gained $0.04 on the day or 2.02% during that session. The CLRB stock price is -64.85% off its 52-week high price of $3.33 and 50% above the 52-week low of $1.01. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.85 Million shares traded. The 3-month trading volume is 1.82 Million shares.
The consensus among analysts is that Cellectar Biosciences, Inc. (CLRB) is a Buy stock at the moment, with a recommendation rating of 1.7. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 5 have rated it as a Hold, with 5 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.15.
Cellectar Biosciences, Inc. (NASDAQ:CLRB) trade information
Sporting 2.02% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, Jan 12 when the CLRB stock price touched $2.10-3 or saw a rise of 3.81%. Year-to-date, Cellectar Biosciences, Inc. shares have moved -2.88%, while the 5-day performance has seen it change 2.54%. Over the past 30 days, the shares of Cellectar Biosciences, Inc. (NASDAQ:CLRB) have changed -7.76%. Short interest in the company has seen 2.64 Million shares shorted with days to cover at 1.45.
Wall Street analysts have a consensus price target for the stock at $5.58, which means that the shares’ value could jump 176.24% from current levels. The projected low price target is $3 while the price target rests at a high of $10. In that case, then, we find that the current price level is +395.05% off the targeted high while a plunge would see the stock lose 48.51% from current levels.
Cellectar Biosciences, Inc. (CLRB) estimates and forecasts
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +59.8% over the past 5 years. Earnings growth for 2021 is a modest +64.9%.
Cellectar Biosciences, Inc. (NASDAQ:CLRB)’s Major holders
Insiders own 13.66% of the company shares, while shares held by institutions stand at 24.14% with a share float percentage of 27.96%. Investors are also buoyed by the number of investors in a company, with Cellectar Biosciences, Inc. having a total of 29 institutions that hold shares in the company. The top two institutional holders are Sio Capital Management, LLC with over 1.36 Million shares worth more than $1.69 Million. As of September 29, 2020, Sio Capital Management, LLC held 5.01% of shares outstanding.
The other major institutional holder is Boxer Capital, LLC, with the holding of over 920Thousand shares as of September 29, 2020. The firm’s total holdings are worth over $1.14 Million and represent 3.37% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. As of September 29, 2020, the former fund manager holds about 0.2% shares in the company for having 53982 shares of worth $66.94 Thousand while later fund manager owns 16.76 Thousand shares of worth $20.78 Thousand as of September 29, 2020, which makes it owner of about 0.06% of company’s outstanding stock.
Even if you’re not actively in crypto, you deserve to know what’s actually going on..
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets are already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.